Related Experiment Video

Updated: Nov 17, 2025

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.0K

Immune checkpoint blockade in renal cell carcinoma

Phillip M Rappold1, Andrew W Silagy1, Ritesh R Kotecha2

  • 1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Journal of Surgical Oncology
|February 17, 2021
PubMed

Insights

Immune checkpoint blockade (ICB) offers long-lasting remission for metastatic renal cell carcinoma (mRCC). New biomarkers are crucial for selecting the best ICB therapies and understanding surgery's role in mRCC treatment.

Area of Science:

  • Oncology
  • Immunology
  • Nephrology

Background:

  • Immune checkpoint blockade (ICB) is a cornerstone therapy for metastatic renal cell carcinoma (mRCC).
  • ICB therapies offer the potential for durable responses in mRCC patients.
  • The increasing number of ICB options necessitates better patient selection strategies.

Purpose of the Study:

  • To review current data on ICB efficacy in RCC.
  • To discuss emerging biomarkers predictive of ICB response.
  • To explore the role of surgery in the context of mRCC and ICB.

Main Methods:

  • Literature review of clinical trials and studies on ICB in RCC.
  • Analysis of data on biomarkers associated with ICB response.
  • Evaluation of surgical approaches in mRCC management.

Main Results:

  • ICB has demonstrated significant efficacy in mRCC, leading to long-term remissions.
  • Several biomarkers are under investigation for predicting ICB response.
  • The role of surgery is being redefined alongside advancements in systemic therapy.

Conclusions:

  • Biomarkers are essential for personalizing ICB treatment in mRCC.
  • A comprehensive understanding of ICB, biomarkers, and surgery is vital for optimizing mRCC care.
Keywords:
biomarkerscytoreductive nephrectomyimmunotherapykidney cancer

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

818
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
860
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.0K